V 01 - Livzon Mabpharm/Institute of Biophysics, Chinese Academy of Sciences
Alternative Names: Recombinant coronavirus fusion protein vaccine - Livzon Mabpharm/Institute of Biophysics, Chinese Academy of Sciences; Recombinant SARS-CoV-2 Fusion Protein Vaccine; V-01; V01 Livzon Mabpharm/Institute of Biophysics, Chinese Academy of SciencesLatest Information Update: 03 May 2023
Price :
$50 *
At a glance
- Originator Institute of Biophysics, Chinese Academy of Sciences; Livzon Mabpharm
- Developer Livzon Mabpharm
- Class COVID-19 vaccines; Protein vaccines; Recombinant fusion proteins; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III COVID 2019 infections
Most Recent Events
- 14 Apr 2023 Livzon Mabpharm completes a phase III trial in COVID-2019 infections (Prevention) in Pakistan and Malaysia (IM) (NCT05096832)
- 29 Jan 2022 Livzon Mabpharm completes phase I trial in COVID-2019 infections (Prevention) in China (IM) (NCT05050474)
- 10 Nov 2021 Livzon Pharmaceutical initiates the phase II COVID-19 trial for COVID-2019 infections (Prevention) in China (IM) (NCT05238649)